Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pazopanib Hydrochloride

FDA-approved product (tablet, oral), marketed as Pazopanib Hydrochloride, Votrient.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pazopanib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Collecting duct carcinoma
  • Papillary renal cell carcinoma
  • Renal cell carcinoma
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pazopanib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pazopanib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

    NCT01446809 · start 2012-04

    Registered record
    Registry ID
    NCT01446809
    Conditions
    Stage IIA Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    Doxorubicin Hydrochloride; External Beam Radiation Therapy; Ifosfamide; Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study; Placebo; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-04
    Completion
    2019-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IIA Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    InterventionDoxorubicin Hydrochloride; External Beam Radiation Therapy; Ifosfamide; Laboratory Biomarker Analysis +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

    NCT01552356 · start 2012-03-19

    Registered record
    Registry ID
    NCT01552356
    Conditions
    Solid Neoplasm
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2012-03-19
    Completion
    2027-03-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Neoplasm
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    PhasePhase 1
    Registry statusActive not recruiting

  • Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

    NCT01532687 · start 2012-03-13

    Registered record
    Registry ID
    NCT01532687
    Conditions
    Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Undifferentiated Pleomorphic Sarcoma; Malignant Adult Hemangiopericytoma; Recurrent Adult Soft Tissue Sarcoma; Sarcoma; Stage III Adult Soft Tissue Sarcoma AJCC v7; Stage IV Adult Soft Tissue Sarcoma AJCC v7
    Interventions
    Gemcitabine; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Pazopanib; Pazopanib Hydrochloride; Placebo Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03-13
    Completion
    2019-10-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma +15 more
    InterventionGemcitabine; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Pazopanib +2 more
    PhasePhase 2
    Registry statusCompleted

  • Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

    NCT01472081 · start 2012-02-09

    Registered record
    Registry ID
    NCT01472081
    Conditions
    Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
    Interventions
    Nivolumab; Pazopanib; Sunitinib; Ipilimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02-09
    Completion
    2021-06-03
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
    InterventionNivolumab; Pazopanib; Sunitinib; Ipilimumab
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

    NCT01436227 · start 2012-01-17

    Registered record
    Registry ID
    NCT01436227
    Conditions
    Von Hippel-Lindau Syndrome
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-01-17
    Completion
    2024-03-13
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVon Hippel-Lindau Syndrome
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

    NCT01465659 · start 2011-12-12

    Registered record
    Registry ID
    NCT01465659
    Conditions
    Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
    Interventions
    temozolomide; pazopanib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-12-12
    Completion
    2021-01-27
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma +1 more
    Interventiontemozolomide; pazopanib hydrochloride
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

    NCT01468909 · start 2011-12-12

    Registered record
    Registry ID
    NCT01468909
    Conditions
    Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    Interventions
    Laboratory Biomarker Analysis; Paclitaxel; Pazopanib Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12-12
    Completion
    2018-01-27
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    InterventionLaboratory Biomarker Analysis; Paclitaxel; Pazopanib Hydrochloride; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

    NCT01413113 · start 2011-12

    Registered record
    Registry ID
    NCT01413113
    Conditions
    Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
    Interventions
    pazopanib hydrochloride; iodine I 131
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-12
    Completion
    2015-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer +3 more
    Interventionpazopanib hydrochloride; iodine I 131
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

    NCT01462630 · start 2011-11-03

    Registered record
    Registry ID
    NCT01462630
    Conditions
    Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    pazopanib hydrochloride; laboratory biomarker analysis; positron emission tomography; computed tomography; fludeoxyglucose F 18
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-11-03
    Completion
    2021-01-12
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventionpazopanib hydrochloride; laboratory biomarker analysis; positron emission tomography; computed tomography +1 more
    PhasePhase 2
    Registry statusCompleted

  • Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

    NCT01636908 · start 2011-08

    Registered record
    Registry ID
    NCT01636908
    Conditions
    Cancer; Advanced Solid Tumors
    Interventions
    Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-08
    Completion
    2019-12-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Advanced Solid Tumors
    InterventionSunitinib; Sorafenib; Erlotinib; Everolimus +6 more
    PhaseNot applicable
    Registry statusCompleted

  • Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

    NCT01394211 · start 2011-07-13

    Registered record
    Registry ID
    NCT01394211
    Conditions
    Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
    Interventions
    anastrozole; pazopanib hydrochloride; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-07-13
    Completion
    2012-04-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer +3 more
    Interventionanastrozole; pazopanib hydrochloride; therapeutic conventional surgery
    PhasePhase 2
    Registry statusTerminated

  • Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

    NCT01208064 · start 2011-07

    Registered record
    Registry ID
    NCT01208064
    Conditions
    Lung Cancer
    Interventions
    pazopanib hydrochloride; laboratory biomarker analysis; pharmacogenomic studies; pharmacological study; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2011-07
    Completion
    2015-06
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionpazopanib hydrochloride; laboratory biomarker analysis; pharmacogenomic studies; pharmacological study +1 more
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

    NCT01340794 · start 2011-05

    Registered record
    Registry ID
    NCT01340794
    Conditions
    Extra-Adrenal Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Paraganglioma; Recurrent Adrenal Gland Pheochromocytoma
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2014-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtra-Adrenal Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Paraganglioma; Recurrent Adrenal Gland Pheochromocytoma
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride
    PhasePhase 2
    Registry statusTerminated

  • Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

    NCT01247571 · start 2011-01

    Registered record
    Registry ID
    NCT01247571
    Conditions
    Recurrent Uterine Corpus Sarcoma; Uterine Carcinosarcoma
    Interventions
    Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2016-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Uterine Corpus Sarcoma; Uterine Carcinosarcoma
    InterventionPazopanib Hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

    NCT01157091 · start 2010-12-08

    Registered record
    Registry ID
    NCT01157091
    Conditions
    Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
    Interventions
    pazopanib hydrochloride; laboratory biomarker analysis; immunologic technique
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12-08
    Completion
    2013-12-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
    Interventionpazopanib hydrochloride; laboratory biomarker analysis; immunologic technique
    PhasePhase 2
    Registry statusCompleted